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A B S T R A C T
Recently incarcerated individuals are at increased risk of opioid overdose. Methadone maintenance treatment
(MMT) is an effective way to address opioid use disorder and prevent overdose; however, few jails and prisons in
the United States initiate or continue people who are incarcerated on MMT. In the current study, the 12 month
outcomes of a randomized control trial in which individuals were provided MMT while incarcerated at the
Rhode Island Department of Corrections (RIDOC) are assessed. An as-treated analysis included a total of 179
participants—128 who were, and 51 who were not, dosed with methadone the day before they were released
from the RIDOC. The results of this study demonstrate that 12 months post-release individuals who received
continued access to MMT while incarcerated were less likely to report using heroin and engaging in injection
drug use in the past 30 days. In addition, they reported fewer non-fatal overdoses and were more likely to be
continuously engaged in treatment in the 12-month follow-up period compared to individuals who were not
receiving methadone immediately prior to release. These findings indicate that providing incarcerated in-
dividuals continued access to MMT has a sustained, long-term impact on many opioid-related outcomes post-
release.
1. Introduction
Prevalence of opioid use disorder (OUD) is exaggerated among
those who are incarcerated (Mumola and Karberg, 2006). Just over
23% of state prisoners report ever using heroin or other opiates and
13% report regular use prior to incarceration (Mumola and Karberg,
2006). In addition, people who have recently been incarcerated are at
extreme risk of overdose during community re-entry (Binswanger et al.,
2007). A recent study that investigated all causes of mortality of people
who were formerly incarcerated in Washington State found that over-
dose was the number one cause of death (Binswanger et al., 2013).
Methadone-maintenance treatment (MMT), the combination of be-
havioral therapy, counseling and methadone provision, is an effective,
evidence-based approach to address opioid use disorder and overdose
(Connock et al., 2007). Numerous studies have documented the far-
reaching benefits to implementing MMT in correctional populations,
including post-incarceration reductions in illicit opioid use (Mattick
et al., 2009; Kinlock et al., 2009), re-incarceration (Deck et al., 2009;
Larney et al., 2012), mortality and overdose (Degenhardt et al., 2011;
Kerr et al., 2007), and HIV risk behaviors (MacArthur et al., 2012)
among others (Rich et al., 2015, Zaller et al., 2013, McKenzie et al.,
2012, Heimer et al., 2006; Dolan et al., 2003).
In the United States (US), there are over 3200 local and county jails
and 1800 state and federal prisons, but few facilities offer addiction
treatment using MMT (Vestal, 2016; Lee et al., 2015). In 2008, less than
0.1% of the total prison population received any form of buprenorphine
or MMT (Larney and Dolan, 2009), and, while 28 state prison systems
make MMT available to those who are incarcerated, a majority restrict
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2.3. Procedures
Participants in the MMT continuation group were maintained on
methadone during incarceration, with adjustments made to their dose
as clinically indicated. Participants who were receiving a stable dose
were continued on the same dose. Those participants whose doses were
being adjusted at the time of incarceration or who had symptoms
caused by doses that were either too low or too high, had adjustments
made in accordance with standard clinical practices, usually in colla-
boration with their community methadone clinic.
Participants who were assigned to standard care (meaning forced
withdrawal from methadone) completed the RIDOC’s standard protocol
for MMT upon entry, which, at the time of the study, included con-
tinuation of entry dose during the first week of incarceration followed
by a tapered withdrawal schedule (e.g., an entry dose of> 100mg
would be reduced by 5mg per day to 100mg, then reduced by 3mg per
day to 0mg). Since the standard taper protocol typically lasted 4–6
weeks or longer, participants in the forced withdrawal group could still
be receiving a daily dose of methadone at the time of release, dependent
on the length of their incarceration and starting dose (e.g., if they were
incarcerated for two weeks). Upon discharge (regardless of study con-
dition), all participants were assisted with transportation, scheduling,
and financing for their first MMT appointment in the community.
All research assessments were administered via face-to-face inter-
views. At enrollment, we asked participants to provide multiple ways to
contact them in the community to increase our chances to conduct
follow-up interviews. Participants provided thorough contact informa-
tion and information about places they liked to “hangout”. This in-
formation was used if phone and mail attempts went unanswered and
was particularly useful for unstably housed participants. To accom-
modate transportation issues, we provided cab or bus fare and met
participants in locations convenient for them to complete the interview.
In addition, we provided participants with business cards with inter-
view dates, reimbursement amount, and research staff contact in-
formation and reminded them of assessments via mail and phone.
Research assessments were conducted at one, six, and 12 months post-
release. All outcomes reported herein are from the 12-month follow-up
interview.
All follow-up interviews took place at a location most convenient to
the participant, such as a private interview space located at The Miriam
Hospital or one of the treatment facilities, a fast food restaurant, or a
participant’s home. Privacy and safety concerns were part of staff
training and were discussed in staff meetings. Follow-up interviews, on
average, lasted about thirty minutes. After each completed assessment,
participants received $20. Additionally, participants could receive $5
for checking in between the one month and six-month study visit and
between the six and 12-month study visit.
2.4. Study population
We enrolled participants between June 2011 and April 2013. A
detailed description of the study population and one-month outcomes
are published elsewhere (Rich et al., 2015). At baseline, there were a
total of 223 participants, and 179 completed a 12-month follow-up
(80.3% retention). Of the 44 participants for whom no 12-month
follow-up interviews were completed, four died of an overdose (two
were on MMT at release and two were not) and one participant died
from violent causes. Seven participants were continuously incarcerated
between the six- and 12- month assessments, and did not complete a 12-
month interview. One participant refused participation in the 12-month
assessment, and we were unable to contact the remaining 31 partici-
pants. There were no statistically significant differences between those
who completed a 12-month interview and those who were lost to
follow-up (data not shown). A total of 51 participants were released
from incarceration after having been completely tapered from metha-
done. These participants, on average, spent 52 days without methadone
treatment to special populations (e.g., pregnant women; Nunn et al., 
2009).
When MMT or other forms of medication for addiction treatment 
(MAT) (Wakeman, 2017; e.g., buprenorphine) are not provided in the 
correctional setting, individuals who are addicted to opioids experience 
symptoms of withdrawal. Opioid withdrawal can include severe phy-
sical discomfort and psychological distress, risk of suicide, and leads to 
loss of opioid tolerance, thereby increasing risk of fatal and non-fatal 
overdose post-release (Merrell et al., 2010). Also, while the current 
literature points to the clear benefit of providing MMT during in-
carceration and linkage to treatment in the community, less is known 
about the long-term effects of MMT access during incarceration.
The objective of the current study was to identify the long-term 
effects of providing access to MMT for people who are incarcerated. 
From 2011–2014, we conducted a randomized control trial to assess the 
impact of continued MMT versus forced withdrawal from methadone in 
people who were incarcerated for six months or less, on fatal and non-
fatal overdose, substance use, emergency department use, treatment 
engagement in the community, and HIV risk behaviors such as injection 
drug use and transactional sex. Baseline results indicated that forced 
withdrawal from MMT reduced the likelihood of MMT engagement 
post-release in the community (Rich et al., 2015). In the current study, 
we present outcomes measured at 12 months following release.
2. Methods
2.1. Study design
The study was conducted at the Rhode Island Department of 
Corrections (RIDOC), a unified, statewide prison and jail system. All 
participants gave written informed consent. This study was approved by 
the Institutional Review Board of the Miriam Hospital in Providence, 
Rhode Island (RI), and the RIDOC Medical Research Advisory Group. In 
addition, the study was reviewed by a data safety monitoring board 
every six months for the first two years of recruitment, then once per 
year until the study ended. This trial is registered with 
ClinicalTrials.gov (number NCT01874964).
Inclusion criteria for the study included being incarcerated for at 
least one week and no more than six months and having been engaged 
in MMT treatment prior to incarceration. At intake, individuals re-
ported to RIDOC nursing staff whether they were enrolled in a MMT 
program before incarceration. Nursing staff then confirmed dosing with 
the community provider. Nursing staff and MMT counselors provided 
study information to eligible participants. The name and facility loca-
tion of individuals who expressed interest were forwarded to the re-
search staff who then followed up with an in-person visit that occurred 
within seven days.
2.2. Enrollment and randomization
After consent was obtained, participants were randomly assigned 
(1:1) using a computer-generated random permutation to either a) 
continued MMT or b) tapered withdrawal from methadone after the 
first week of incarceration, the standard of care at the RIDOC at the 
time. Study staff worked in tandem and randomly assigned participants 
to each group—meaning that separate study staff members completed 
enrollment and randomization. The same staff member who enrolled 
the participant followed up with him or her in the community post-
release. Because there were more men than women and few racial 
minorities were enrolled in MMT and incarcerated during the study 
period, urn randomization was used to stratify individuals on the basis 
of sex and race. Urn randomization is appropriate, given that it can 
balance groups with several covariates and has a low risk of experi-
menter bias or manipulation (Wei and Lachin, 1988).




Self-reported sociodemographic data collected included sex, age,
race/ethnicity, health insurance status, and educational attainment
2.5.2. Drug treatment
At enrollment, all participants provided written consent for the re-
search team to access their methadone records at community clinics
post-release. We used these data to assess treatment engagement and
retention throughout the study period. We also measured self-reported
engagement in other treatment modalities (e.g., outpatient and re-
sidential) and engagement in peer support programs such as Alcoholics
Anonymous or Narcotics Anonymous. Continuous enrollment in MMT
was defined as being in treatment for at least 335 days during the 12-
month study period (allowing for 30 days post-release to enroll in
treatment) based on MMT administrative records (matched using first
and last name and date of birth).
2.5.3. Substance use behaviors, overdose, and HIV risk
Substance use data were obtained via the Addiction Severity Index
(ASI). The ASI is a self-report questionnaire that asks about drug use in
the past 30 days (McLellan et al., 1980). HIV risk behaviors (engage-
ment in transactional sex and injection drug use in the past 30 days)
were also measured via self-report. Similarly, non-fatal overdose was
assessed via self-report, but participants were asked to report any non-
fatal overdoses during the entire (12 month) follow-up period. Fatal
overdose was determined through medical examiner reports (matched
using first and last name and date of birth).
2.5.4. Legal status
We asked participants to self-report re-arrest and re-incarceration.
In addition, we obtained re-incarceration data from RIDOC (matched
using first and last name and date of birth), which are publically
available upon request.
2.5.5. Emergency department usage
Participants self-reported utilizing the emergency department in the
past 12 months. Additionally, participants signed releases, permitting
the study team to obtain emergency department data (matched using
first and last name and date of birth) from RI’s largest hospital facilities.
2.6. Outcomes and analysis
For this analysis, outcomes of interest at 12 months included en-
gagement in MMT, re-arrest, re-incarceration, fatal and non-fatal
overdose, emergency department usage, substance use, and HIV risk
behaviors (including transactional sex and injection drug use). We
analyzed outcomes with the χ2 test to assess differences between those
who were 1) randomized to MMT or forced withdrawal from metha-
done (intent-to-treat) and 2) on MMT at release and those who were not
(as-treated).
The intent-to-treat analysis included all eligible participants in the
study as randomized. The as-treated analysis included all eligible par-
ticipants in the study by their methadone status on the day before their
release: either receiving any dose of methadone or not receiving me-
thadone. This type of analysis was conducted because participants in
the forced withdrawal group could still be receiving some amount of
methadone just before their release if they had not yet completed the
RIDOC’s withdrawal protocol (see Rich et al., 2015 for a more in-depth
explanation of randomization and baseline procedures).
3. Results
A majority of participants who completed the 12-month follow-up
were male (78.2%), White (78.8%), and had not finished high school
(39.7%). The median age of all participants at baseline was 32.6 years
[IQR: 28.4, 40.9]. See Table 1 for all participant demographic details.
Those who received methadone on the day before release were sig-
nificantly more likely than those not dosed with methadone on the day
before release to have been incarcerated for a shorter period of time.
When analyzed by randomization status (MMT versus forced with-
drawal), no significant differences were found between groups (data
not shown).
3.1. Intent-to-treat analysis
Of the participants assigned to the continued MMT group (n=96),
43.6% were engaged in continuous MMT at 12 months, whereas only
38.8% of the forced withdrawal group (n=83) were. A lower pro-
portion of those in the continued MMT group were re-incarcerated,
utilized the emergency department, used heroin, and reported injection
drug use at 12 months than those in the forced withdrawal group;
however, none of these differences were significant (see Table 2 for all
intent-to-treat analyses).
Total (N=179) Dosed with methadone day before release
n=128




Male 140 (78.2%) 98 (76.6%) 42 (82.4%) 0.3986
Female 39 (21.8%) 30 (23.4%) 9 (17.7%) 0.3986
Ethnic origin
White 141 (78.8%) 101 (78.9%) 40 (78.4%) 0.9439
Black 8 (4.5%) 5 (3.9%) 3 (5.9%) 0.5661
Other 30 (16.8%) 22 (17.2%) 8 (15.7%) 0.5501
Hispanic 25 (14.0%) 19 (14.8%) 6 (11.8%) 0.5925
Age at baseline (years), median (IQR) 32.6 (28.4, 40.9) 32.1 (27.8, 40.6) 35.4 (30.3, 42.2) 0.0843
Duration of incarceration (days), median
(IQR)
45 (16, 79) 30.0 (14.0, 58.5) 80 (57.0, 116.0) <0.001
Number of years in education
Did not finish high school 71 (39.7%) 52 (40.6%) 19 (37.3%) 0.6775
Finished high school 68 (38.0%) 48 (37.5%) 20 (39.2%) 0.8310
College or higher education 40 (22.4%) 28 (21.9%) 12 (23.5%) 0.8105
Table 1
Baseline Sociodemographic Characteristics of Patients.
3.2. As-treated analysis
When data were analyzed by methadone status at release (receiving
or not receiving methadone), at 12 month follow-up, those who re-
ceived MMT on the day before release (n=128) were significantly less
likely than those not dosed with methadone the day before release
(n=51) to report using heroin (p= .0467) and injecting drugs in the
past 30 days (p= .0033), and were significantly less likely to have had
a non-fatal overdose in the 12 months follow-up period (7% vs 18%,
p= .0390). Those who received methadone on the day before release
were significantly more likely than those not dosed with methadone on
the day before release to engage continuously in MMT during the 12-
month follow-up period (p= .0211) (see Table 3). There were no dif-
ferences between study groups for re-incarceration, visits to the emer-
gency department, transactional sex, or use of prescription opioids,
alcohol, cannabis, or other drugs.
4. Discussion
The objective of this study was to identify the long-term (12
months) effects of providing access to MMT to people who are in-
carcerated before their release into the community. The results of this
study demonstrate that 12 months post-release individuals who re-
ceived MMT while incarcerated were less likely to report heroin and
injection drug use in the past 30 days and experienced fewer non-fatal
overdoses. They were also more likely to be continuously engaged in
MMT in the community. These findings indicate that providing in-
carcerated individuals access to MMT prior to release with linkage to
treatment in the community is a successful strategy to address the
growing opioid epidemic and lessen long-term risk.
Our results corroborate previous research from our group and others
that demonstrate the benefits of MMT among those with recent in-
carceration (Rich et al., 2015, Kinlock et al., 2008). Access to opioid
pharmacotherapies while incarcerated significantly reduces mortality,
both while incarcerated and post-release, and decreases likelihood of
engaging in HIV risk behaviors (Marsden et al., 2017; McKenzie et al.,
2012; Degenhardt et al., 2014; Larney et al., 2014; Larney, 2010). In
addition, incarceration is often cited as a factor that can increase risk
behavior. For instance, those with a history of incarceration are more
likely to share used needles during community reentry (Milloy et al.,
2009) and individuals leaving incarceration have a multi-fold increased
risk of overdose than the general population and at other times of active
drug use (Binswanger et al., 2013; Connock et al., 2007; Wakeman,
2017). Therefore, providing MMT and other forms of MAT may de-
crease mortality and risk behaviors and negate the possible adverse
effect incarceration itself can have on substance use related health
outcomes. However, to date, robust MMT programs in correctional
settings are rare in the US. This study contributes to a growing body of
evidence by demonstrating that access to MMT during incarceration
can have a sustained long-term impact.
While we did find that those who received MMT on the day before
their release were more likely to engage in continuous treatment during
the follow- up period, the effects were modest. Only 45% of those who
received MMT the day before release and 26% of those who did not
were continuously engaged in treatment. Financial stressors may have
impacted access to treatment in the community long-term. At the time
of the study, most individuals leaving incarceration did not have
medical insurance, as many were in enrolled in a state funded treatment
program, to which they lost access while incarcerated. To ensure that
financial concerns were not a barrier immediately upon release, the
Continued methadone n= 96 Forced methadone withdrawal
n=83
Unadjusted Odds Ratio (OR) (95% CI)
Drug treatment (prior 12 months)
Outpatient drug-free program 21 (21.9%) 12 (14.5%) 1.66 (0.76, 3.61)
Residential treatment program 23 (24.0%) 12 (14.5%) 1.86 (0.86, 4.03)
Prison/jail treatment program 1 (1.0%) 1 (1.2%) 0.86 (0.05, 14.01)
Self-help/12-step program 37 (38.5%) 31 (37.4%) 1.05 (0.57, 1.93)
In methadone treatment program 87 (90.6%) 73 (88.0%) 1.32 (0.51, 3.43)
In any drug treatment program 90 (93.8%) 76 (91.6%) 1.38 (0.44, 4.29)
Detox program (prior 12 months) 16 (16.7%) 13 (15.7%) 1.08 (0.48, 2.39)
Continuous engagement in methadone treatment programa
(n=174)
41 (43.6%) 31 (38.8%) 1.22 (0.67, 2.24)
Health insurance (prior 12 months) 46 (47.9%) 49 (59.0%) 0.64 (0.35, 1.16)
Opioid replacement therapy (prior 30 days)
Prescribed methadone 64 (66.7%) 56 (67.5%) 0.96 (0.52, 1.80)
Prescribed buprenorphine 2 (2.1%) 6 (7.2%) 0.27 (0.05, 1.39)
Adverse events (prior 12 months)
Re-arrested 47 (49.0%) 47 (56.6%) 0.74 (0.41, 1.33)
Reincarcerated (self-report) 26 (27.1%) 31 (37.4%) 0.62 (0.33, 1.17)
Reincarcerated (administrative data) 55 (57.3%) 48 (57.8%) 0.98 (0.54, 1.77)
Emergency department utilization (self-report) 41 (42.7%) 37 (44.6%) 0.93 (0.51, 1.68)
Emergency department utilization(administrative data) 36 (37.5%) 34 (41.0%) 0.87 (0.47, 1.58)
Drug use at 12 months (prior 30 days)
Heroin 27 (28.1%) 24 (28.9%) 0.96 (0.50, 1.84)
Prescription opioids 12 (12.5%) 12 (14.5%) 0.85 (0.36, 2.00)
Alcohol to feel effects 21 (21.9%) 13 (15.7%) 1.51 (0.70, 3.24)
Cannabis use 30 (31.3%) 26 (31.3%) 1.00 (0.53, 1.88)
Other drug useb 36 (37.5%) 42 (50.6%) 0.59 (0.32, 1.06)
HIV risk behaviors (prior 30 days)
Injection drug use 20 (20.8%) 23 (27.7%) 0.69 (0.35, 1.37)
Transactional sexc 2 (2.1%) 1 (1.2%) 1.75 (0.16, 19.59)
Overdoses (nonfatal) 6 (6.3%) 12 (14.5%) 0.39 (0.14, 1.10)
*p < .05.
a=Defined as≥335 total days in treatment during study period; 5 records were excluded due to incomplete data.
b= Includes use of barbiturates; sedatives, hypnotics, or tranquilizers; benzodiazepines; cocaine or crack; amphetamines; hallucinogens; or inhalants.
c= Includes sex in exchange for drugs, money, or food/shelter.
Abbreviations;: IQR= interquartile range; CI= confidence interval.
Table 2
Intent-to-Treat Clinical Outcomes Measured at 12 Months after Release from Incarceration.
study paid for the first 10-weeks of MMT for participants who did not
have insurance; however, financial limitations could have restricted
access to MMT in the community after 10 weeks. In RI, because of the
passage of the Affordable Care Act and the subsequent expansion of
Medicaid, many people released from the RIDOC are now eligible for
health insurance, rendering costs less of an issue. However, in many
states with the highest rates of incarceration, Medicaid was not ex-
panded, and the cost of MMT continues to be a barrier to treatment
engagement and sustainment in those states (Cuellar and Cheema,
2012; Rich et al., 2014). It is imperative that post-release linkage to
MMT is treatment is included in future MMT programs. In addition,
supportive services that address financial and other barriers that may
prohibit long term engagement in MMT should be considered essential.
Many studies have demonstrated that access to MAT during in-
carceration can lessen short-term risk of overdose and risky opioid use
behaviors (Rich et al., 2015; Zaller et al., 2013; McKenzie et al., 2012).
Our results extend these findings and demonstrate that access to MMT
can lessen risk in the first-year post-release and affect engagement in
continuous MMT in the community. In response to the increasing
number of overdose deaths in the US, many states have developed
strategic initiatives to lower risk. However, few jails and prisons offer
comprehensive MAT programs, and to our knowledge, RI is one of the
only states that has explicitly incorporated corrections-based re-
commendations into their overdose reduction plan. In 2015, the gov-
ernor of RI created the Overdose Prevention and Intervention Task
Force with the goal of reducing opioid overdose deaths by one third
after three years (Rhode Island Governor's Overdose Prevention and
Intervention Task Force, 2015). A key component of the task force’s
recommendations was a comprehensive MAT initiative that included
making available methadone, buprenorphine, and naltrexone to all
eligible individuals. The findings of the current study provide evidence
to support the creation and expansion of similar comprehensive pro-
grams in other correctional settings across the country.
4.1. Study limitations and other considerations
We could not control for the duration of incarceration, and many
(41%) participants who were assigned to the forced withdrawal group
were released before completing the standard MMT taper protocol. At
the time that this study was conducted, the standard taper protocol was
to gradually taper methadone at RIDOC; however, in most US jur-
isdictions, MMT is abruptly stopped upon incarceration, which might
lead to an even greater effect of MMT access for those incarcerated for
shorter periods. The results of the as-treated analysis lend support to
this theory.
Several factors may limit the generalizability of this study.
Recruiting and conducting research in correctional facilities can present
significant challenges (McKenzie et al., 2009). Because of this, our
sample size was smaller than anticipated. Also, this study was con-
ducted in RI where a larger proportion of incarcerated individuals are
White, which is very different than other states (Zaller et al., 2009). In
addition, this study took place at the RIDOC, a unique state-wide uni-
fied prison and jail system, and only included participants who were at
the RIDOC for six months or less; consequently, prisoners with longer
sentences were not included. We acknowledge that there were differ-
ences in length of sentence between those who received methadone on
the day before release and those who did not. Length of sentence has
been shown to play a role in risk of overdose post-release as those who
Dosed with methadone day before
release n= 128
Not dosed with methadone day before
release n=51
Unadjusted Odds Ratio (OR)
(95% CI)
Drug treatment (prior 12 months)
Outpatient drug-free program 28 (21.9%) 5 (9.8%) 0.39 (0.14, 1.07)
Residential treatment program 24 (18.8%) 11 (21.6%) 1.19 (0.53, 2.65)
Prison/jail treatment program 0 (0%) 2 (3.9%) –
Self-help/12-step program 46 (35.9%) 22 (43.1%) 1.35 (0.70, 2.62)
In methadone treatment program 117 (91.4%) 43 (84.3%) 0.51 (0.19, 1.34)
In any drug treatment program 120 (93.8%) 46 (90.2%) 0.61 (0.19, 1.97)
Detox program (prior 12 months) 21 (16.4%) 8 (15.7%) 0.95 (0.39, 2.30)
Continuous engagement in methadone treatment
programa (n= 174)
56 (45.2%) 13 (26.0%) 0.43 (0.21, 0.88)*
Health insurance (prior 12 months) 67 (52.3%) 28 (54.9%) 1.11 (0.58, 2.13)
Opioid replacement therapy (prior 30 days)
Prescribed methadone 88 (68.8%) 32 (62.8%) 0.77 (0.39, 1.51)
Prescribed buprenorphine 4 (3.1%) 4 (7.8%) 2.64 (0.63, 11.0)
Adverse events (prior 12 months)
Re-arrested 65 (50.8%) 29 (56.9%) 1.28 (0.67, 2.46)
Reincarcerated (self-report) 39 (30.5%) 18 (35.3%) 1.25 (0.63, 2.47)
Reincarcerated (administrative data) 72 (56.3%) 31 (60.8%) 1.21 (0.62, 2.34)
Emergency department utilization (self-report) 52 (40.6%) 26 (51.0%) 1.52 (0.79, 2.92)
Emergency department utilization (administrative
data)
52 (40.6%) 18 (35.3%) 0.80 (0.41, 1.56)
Drug use at 12 months (prior 30 days)
Heroin 31 (24.2%) 20 (39.2%) 2.02 (1.01, 4.04)*
Prescription opioids 18 (14.1%) 6 (11.8%) 0.82 (0.30, 2.19)
Alcohol to feel effects 25 (19.5%) 9 (17.7%) 0.88 (0.38, 2.05)
Cannabis use 45 (35.2%) 11 (21.6%) 0.51 (0.24, 1.08)
Other drug useb 50 (39.1%) 28 (54.9%) 1.90 (0.99, 3.66)
HIV risk behaviors (prior 30 days)
Injection drug use 23 (18.0%) 20 (39.2%) 2.95 (1.43, 6.06)*
Transactional sexc 2 (1.6%) 1 (2.0%) 1.26 (0.11, 14.2)
Overdoses (nonfatal) 9 (7.0%) 9 (17.7%) 2.83 (1.05, 7.61)*
*p < .05.
a=Defined as≥335 total days in treatment during study period; 5 records were excluded due to incomplete data
b= Includes use of barbiturates; sedatives, hypnotics, or tranquilizers; benzodiazepines; cocaine or crack; amphetamines; hallucinogens; or inhalants.
c= Includes sex in exchange for drugs, money, or food/shelter.
Abbreviations;: IQR= interquartile range; CI= confidence interval.
Table 3
As-Treated Clinical Outcomes Measured at 12 Months after Release from Incarceration.
5. Conclusion
The US is experiencing an epidemic of escalating opioid use, and
those who have recently been incarcerated are at increased risk of
overdose and risky drug use post-release. Nonetheless, access to MMT
in correctional settings or upon discharge remains rare in the US. Our
findings indicate that providing MMT to individuals who are in-
carcerated can affect long-term outcomes including continuous treat-
ment engagement, using heroin, injecting drugs, and non-fatal overdose
in the first year after release. Based on the findings of the current study,
more states should partner with correctional institutions to create or
expand programs that provide incarcerated, opioid dependent in-
dividuals with access to MMT and provide linkage to treatment pro-
grams in the community upon release.
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